| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Product Type | |
| Promoter | |
| Selection Marker | Puromycin |
| Shipping | |
| Species |
Background
IL2RG encodes the interleukin-2 receptor common gamma chain (γc), a shared signaling subunit of the receptors for interleukins 2, 4, 7, 9, 15, and 21. Through these cytokine receptors, γc couples to JAK3 and the STAT family of transcription factors to drive lymphocyte development, survival, and proliferation. Loss-of-function mutations in IL2RG cause X-linked severe combined immunodeficiency (X-SCID), which is characterized by a profound failure of T cell and natural killer cell development. Because of its central role in immune signaling, IL2RG is widely studied in immunology, hematopoiesis, gene therapy, and cancer research.
Product Description & Applications
The IL2RG ORF cDNA Lentivirus delivers the full human IL2RG open reading frame for stable overexpression in mammalian cells. Expression is driven by a CMV promoter, and constructs may include a C-terminal epitope tag, a fluorescent reporter such as EGFP or mCherry, and a puromycin selection marker; tag, reporter, and marker elements are linked by self-cleaving peptide sequences for independent translation from a single transcript. Supplied as high-titer, third-generation, VSV-G-pseudotyped particles in serum-free RPMI-1640, the virus efficiently transduces primary, thawed, and otherwise difficult-to-transfect cells.
It supports stable cell line generation for gain-of-function studies of common gamma chain cytokine signaling, immune cell biology, and in vitro or in vivo applications.
About This Product
This ORF cDNA lentivirus enables stable overexpression of IL2RG (NCBI Accession: NM_000206.3) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (CMV). Reporter and selection marker components (GFP or RFP; Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.
Ultra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
